MX370928B - El uso de 9-cis-retinil acetato para mejorar la función visual de un sujeto que padece de pérdida de la función visual originada por una deficiencia retinoide endógena de 11-cis retinal. - Google Patents

El uso de 9-cis-retinil acetato para mejorar la función visual de un sujeto que padece de pérdida de la función visual originada por una deficiencia retinoide endógena de 11-cis retinal.

Info

Publication number
MX370928B
MX370928B MX2014010457A MX2014010457A MX370928B MX 370928 B MX370928 B MX 370928B MX 2014010457 A MX2014010457 A MX 2014010457A MX 2014010457 A MX2014010457 A MX 2014010457A MX 370928 B MX370928 B MX 370928B
Authority
MX
Mexico
Prior art keywords
disorders associated
methods
visual
therapeutic regimens
deficiency
Prior art date
Application number
MX2014010457A
Other languages
English (en)
Other versions
MX2014010457A (es
Inventor
Cadden Suzanne
Original Assignee
Retinagenix LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Retinagenix LLC filed Critical Retinagenix LLC
Publication of MX2014010457A publication Critical patent/MX2014010457A/es
Publication of MX370928B publication Critical patent/MX370928B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

Se describen regímenes terapéuticos para mejorar la función visual en un sujeto que tiene una deficiencia en 11-cis-retinal endógenamente producido, que comprenden administrar el derivado retinal sintético como una dosis dividida durante 2-7 días, después proporcionar un período de descanso de 7-28 días, después de lo cual se administra la segunda dosis del derivado retinal sintético. Los derivados retinal sintéticos preferidos son 9- u 11-cis-retinil ésteres. Los trastornos asociados con la deficiencia en 11-cis-retinal endógenamente producido incluyen retinitis pigmentosa y amaurosis congénita de Leber.
MX2014010457A 2012-03-01 2013-03-01 El uso de 9-cis-retinil acetato para mejorar la función visual de un sujeto que padece de pérdida de la función visual originada por una deficiencia retinoide endógena de 11-cis retinal. MX370928B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261605729P 2012-03-01 2012-03-01
US201261642212P 2012-05-03 2012-05-03
US201261644360P 2012-05-08 2012-05-08
PCT/CA2013/050155 WO2013134867A1 (en) 2012-03-01 2013-03-01 Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency

Publications (2)

Publication Number Publication Date
MX2014010457A MX2014010457A (es) 2015-04-08
MX370928B true MX370928B (es) 2020-01-08

Family

ID=49160185

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010457A MX370928B (es) 2012-03-01 2013-03-01 El uso de 9-cis-retinil acetato para mejorar la función visual de un sujeto que padece de pérdida de la función visual originada por una deficiencia retinoide endógena de 11-cis retinal.

Country Status (17)

Country Link
US (2) US20160296478A1 (es)
EP (1) EP2819667B8 (es)
JP (3) JP6576636B2 (es)
KR (1) KR102133608B1 (es)
CN (2) CN109248163A (es)
AU (3) AU2013232697B2 (es)
BR (1) BR112014021602A2 (es)
CA (1) CA2865935C (es)
DK (1) DK2819667T3 (es)
ES (1) ES2780357T3 (es)
HK (1) HK1205469A1 (es)
IL (1) IL234306B (es)
MX (1) MX370928B (es)
NZ (1) NZ629267A (es)
PT (1) PT2819667T (es)
RU (1) RU2635536C2 (es)
WO (1) WO2013134867A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2622763C2 (ru) 2010-04-19 2017-06-19 Новелион Терапьютикс Инк. Лечебная схема и способы лечения или уменьшения нарушений зрения, связанных с дефицитом эндогенных ретиноидов
WO2013134867A1 (en) 2012-03-01 2013-09-19 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
WO2015164419A1 (en) * 2014-04-22 2015-10-29 Acucela Inc. Pupillometric assessment of retinal pharmacodynamics and responses therefrom
US20190054056A1 (en) * 2015-05-08 2019-02-21 University Of Debrecen Precursor compounds for providing retinoids of the vatamin a5 pathway and uses thereof
US20180170867A1 (en) * 2015-05-08 2018-06-21 University Of Debrecen Stereoselective synthesis of 9-cis.13,14-dihydroretinoic acid and its ethyl esters
CA3082441A1 (en) 2016-11-17 2018-05-24 University Of Debrecen Precursor compounds for providing retinoids of the vitamin a5 pathway and uses thereof
RU186184U1 (ru) * 2018-06-06 2019-01-11 Федеральное государственное бюджетное учреждение "33 Центральный научно-исследовательский испытательный институт" Министерства обороны Российской Федерации Устройство для оценки углов обзора и поля зрения испытателей в противогазе

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196078A (en) 1962-01-30 1965-07-20 Ortho Pharma Corp Process for combating retinits pigmentosa
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DE2300107C2 (de) 1973-01-03 1982-03-11 Basf Ag, 6700 Ludwigshafen Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
CH590222A5 (es) 1973-08-21 1977-07-29 Hoffmann La Roche
US4022913A (en) 1973-09-13 1977-05-10 Hoffmann-La Roche Inc. High potency vitamin A compositions
DE2456959A1 (de) 1974-12-03 1976-06-16 Basf Ag 4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
CA1198859A (en) 1982-04-21 1986-01-07 Chester L. O'neal Disposable toothbrush with cap
US4532133A (en) 1983-05-24 1985-07-30 Basf Wyandotte Corporation Low temperature stable, emulsifiable vitamin A concentrates
CA1282326C (en) 1984-12-14 1991-04-02 Paul J. Jarosz Pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient
JPS61275266A (ja) 1985-05-28 1986-12-05 Taisho Pharmaceut Co Ltd レチノイド誘導体
CZ282548B6 (cs) 1992-01-22 1997-08-13 F. Hoffmann-La Roche Ag Farmaceutický přípravek
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja) 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンａ類可溶化点眼剤
EP0754046A1 (en) 1994-04-04 1997-01-22 FREEMAN, William R. Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
RU2106843C1 (ru) 1994-06-29 1998-03-20 Красноярская государственная медицинская академия Способ лечения близорукости
JPH08198746A (ja) 1995-01-18 1996-08-06 Lion Corp 可溶化点眼剤
US5837728A (en) 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US5620970A (en) 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
EP0839029A1 (en) 1995-07-20 1998-05-06 PHARMACIA & UPJOHN COMPANY Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules
US5716627A (en) 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
EP0908179A1 (en) 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
ZA989513B (en) 1997-10-21 1999-04-21 Alcon Lab Inc Compositions containing histamine H2 agonists and methods of use in treating dry eye
US6391924B1 (en) 1997-12-10 2002-05-21 Hampar Karageozian Taurine derivatives useable in the treatment of ophthalmic disorders
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6372463B1 (en) 1999-05-06 2002-04-16 The President & Fellows Of Harvard College Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
US6300328B1 (en) 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
US20020028849A1 (en) 2000-04-18 2002-03-07 Godkin James D. Use of retinol in assisted-reproduction protocols
US6696069B2 (en) 2000-06-30 2004-02-24 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
US20040077604A1 (en) 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
WO2002055540A1 (en) 2001-01-11 2002-07-18 Chebigen Inc. New retinol derivatives, the method of preparations and the uses thereof
EP1381276A4 (en) 2001-04-13 2005-02-02 Univ Pennsylvania METHOD FOR TREATMENT OR DEVELOPMENT SLUDGE DEGRADATION
ITMI20012366A1 (it) 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
CA2468562C (en) 2001-11-30 2011-12-20 Zaihui Zhang Hydrazonopyrazole derivatives and their use as therapeutics
WO2003059336A1 (en) 2002-01-18 2003-07-24 Tatton Technologies, Llc. Methods for treating eye disorders
US20030215413A1 (en) 2002-03-22 2003-11-20 L'oreal Compositions containing stabilized retinoid
US20040097587A1 (en) 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
KR20040095250A (ko) 2002-03-29 2004-11-12 맥심 파마수티컬즈 인크. 안내 손상의 치료 및 예방에 사용하기 위한 활성 산소대사물(ｒｏｍ)의 생성 및 방출 억제제의 용도
JP3854524B2 (ja) 2002-04-01 2006-12-06 ピアス株式会社 油溶性成分安定化組成物及びその組成物を配合した化粧料、並びに油溶性成分の安定化方法
EP1367493A1 (en) 2002-05-30 2003-12-03 STMicroelectronics Limited Prefetch buffer
EP1527774A1 (en) 2003-11-03 2005-05-04 Basilea Pharmaceutica AG New formulation for retinoid-containing soft gelatin capsules
AU2004222279B2 (en) 2003-03-14 2010-01-21 University Of Washington Retinoid replacements and opsin agonists and methods for the use thereof
EP1510133A1 (en) 2003-09-01 2005-03-02 Belovo S.A., Egg Science & Technology Balanced oil composition
WO2005023094A2 (en) 2003-09-04 2005-03-17 The Uab Research Foundation Method and apparatus for the detection of impaired dark adaptation
US7706863B2 (en) 2004-01-21 2010-04-27 University Of Washington Methods for assessing a physiological state of a mammalian retina
WO2005079774A2 (en) 2004-02-17 2005-09-01 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
EP1723096A4 (en) 2004-03-04 2008-03-05 Htl High Tech Lipids Ltd TRIGLYCERIDES STRUCTURES AND EMULSIONS CONTAINING THESE TRIGLYCERIDES
EP1727529B1 (en) 2004-03-17 2016-03-02 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
BRPI0511396B1 (pt) * 2004-06-18 2021-07-27 University Of Washington Uso de 9-cis-retinil éster e uso de um derivado de retinal sintético
PL1768657T3 (pl) 2004-06-23 2009-01-30 Revision Therapeutics Inc Sposoby i kompozycje do leczenia stanów ocznych za pomocą pochodnych retinylowych
US20060240098A1 (en) 2004-07-14 2006-10-26 Aphios Corporation Formulations for hyperforin-enriched hypericum fractions
JP2008515778A (ja) 2004-08-18 2008-05-15 シリオン セラピューティクス， インコーポレイテッド 眼の状態を１３−シス−レチニル誘導体で処置するための組み合わせ方法、組成物および治療
WO2006039551A2 (en) * 2004-09-30 2006-04-13 The Regents Of The University Of California Local administration of retinoids to treat deficiencies in dark adaptation
US20060177392A1 (en) 2005-02-10 2006-08-10 William Walden Oil-based composition for acne
WO2007056242A1 (en) 2005-11-07 2007-05-18 Murty Pharmaceuticals, Inc. Improved delivery of tetrahydrocannabinol
US8202541B2 (en) 2006-02-07 2012-06-19 U.S. Nutraceuticals, LLC Dietary supplement composition for blood lipid health
WO2008013983A2 (en) 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Opsin stabilizing compounds and methods of use
WO2008087493A1 (en) 2007-01-15 2008-07-24 Chongxi Yu Positively charged water-soluble prodrugs of retinoids and retinoid-like compounds with very high skin penetration rates
PT2187880E (pt) 2007-09-12 2014-03-25 Univ Columbia Composições e métodos para o tratamento da degenerescência macular
RU2565448C2 (ru) * 2008-02-11 2015-10-20 Юниверсити Оф Вашингтон Способы лечения и предупреждения обусловленной возрастом дисфункции сетчатки
MX2012003220A (es) 2009-09-15 2012-08-03 Quadra Logic Tech Inc Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo de lipido.
FR2955459B1 (fr) 2010-01-28 2013-11-22 Polaris Composition huileuse riche en monoglycerides de dha
RU2622763C2 (ru) 2010-04-19 2017-06-19 Новелион Терапьютикс Инк. Лечебная схема и способы лечения или уменьшения нарушений зрения, связанных с дефицитом эндогенных ретиноидов
WO2013134867A1 (en) 2012-03-01 2013-09-19 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
US20150038582A1 (en) 2012-03-01 2015-02-05 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency

Also Published As

Publication number Publication date
AU2018200415A1 (en) 2018-02-08
JP2017197588A (ja) 2017-11-02
CA2865935C (en) 2021-12-14
AU2018200415B2 (en) 2019-09-26
NZ629267A (en) 2016-11-25
ES2780357T3 (es) 2020-08-25
KR102133608B1 (ko) 2020-07-13
RU2635536C2 (ru) 2017-11-13
AU2013232697B2 (en) 2017-10-19
AU2019283995B2 (en) 2021-11-11
JP2015508783A (ja) 2015-03-23
BR112014021602A2 (pt) 2021-06-08
JP2020073597A (ja) 2020-05-14
CA2865935A1 (en) 2013-09-19
CN104470511A (zh) 2015-03-25
EP2819667A1 (en) 2015-01-07
US20160296478A1 (en) 2016-10-13
EP2819667B8 (en) 2020-03-04
AU2013232697A1 (en) 2014-09-18
EP2819667A4 (en) 2015-08-05
MX2014010457A (es) 2015-04-08
HK1205469A1 (en) 2015-12-18
DK2819667T3 (da) 2020-03-30
IL234306B (en) 2022-02-01
PT2819667T (pt) 2020-03-31
JP6576636B2 (ja) 2019-09-18
US10828267B2 (en) 2020-11-10
RU2014139666A (ru) 2016-04-20
EP2819667B1 (en) 2019-12-25
CN109248163A (zh) 2019-01-22
KR20150000881A (ko) 2015-01-05
US20190054039A1 (en) 2019-02-21
WO2013134867A1 (en) 2013-09-19
AU2019283995A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
MX370928B (es) El uso de 9-cis-retinil acetato para mejorar la función visual de un sujeto que padece de pérdida de la función visual originada por una deficiencia retinoide endógena de 11-cis retinal.
GEP201706768B (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
GB201111485D0 (en) Drug composition and its use in therapy
MX336347B (es) Metodo para atenuar los efectos adversos del farmaco usando los acidos grasos omega-3 como un vehiculo terapeutico parenteral del farmaco.
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
WO2014190163A3 (en) Combination therapy for mds
EP3038636A4 (en) Administration of kynurenine depleting enzymes for tumor therapy
IN2014MN00333A (es)
AU2013218357A8 (en) Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors
PH12015500590B1 (en) Apixaban liquid formulations
EP3291835A4 (en) NKT CELL SUBASSEMBLY FOR PERSISTENCE AND THERAPEUTIC ACTIVITYIN VIVO
NZ603331A (en) Therapeutic regimens and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
WO2012006585A3 (en) Use of interleukin-15 to treat cardiovascular diseases
WO2014205109A3 (en) Compositions and methods for the treatment and management of steatosis in human liver
WO2015031413A3 (en) Transdermal delivery of anastrozole for systemic effect
MX351512B (es) Composición para el tratamiento de las verrugas.
NZ741606A (en) Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
UA75277U (ru) Способ лечения дистрофических заболеваний сетчатки и хориоидеи
UA77438U (ru) Способ профилактики возникновения патологических рубцов, локализованных в области головы и шеи после плановых оперативных вмешательств
GB201319244D0 (en) A cosmetic formulation with multiple therapeutic active ingredients with synergistic effects for the treatment of skin ageing
UA72300U (ru) Способ лечения пролиферативной витреоретинопатии при травмах глазного яблока в раннем пост-травматическом периоде
IN2014CN04693A (es)
UA52521U (ru) Способ лечения гипоксического поражения центральной нервной системы у новорожденных детей
AU2011902050A0 (en) Oral administration of low dose of testosterone or other androgens for the prevention and treatment of sarcopaenia to stimulate liver-mediated anabolism and avoid adverse systemic effects

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: BIOSENTA INC.

PD Change of proprietorship

Owner name: RETINAGENIX, LLC,